Kobold, S. RORing CAR T cells in solid and hematologic cancers: Same but different. Clin. Cancer Res. 31, 437-438 (2025)
Bartos, L.M.* et al. Remote neuroinflammation in newly diagnosed glioblastoma correlates with unfavorable clinical outcome. Clin. Cancer Res. 30, 4618-4634 (2024)
Huang, Y.J.* et al. Targeting c-MET for endoscopic detection of dysplastic lesions within Barrett's esophagus using EMI-137 fluorescence imaging. Clin. Cancer Res. 31, 98-109 (2024)
Tawk, B.* et al. DNA-methylome–based tumor hypoxia classifier identifies HPV-negative head and neck cancer patients at risk for locoregional recurrence after primary radiochemotherapy. Clin. Cancer Res. 29, 3051-3064 (2023)
Wang, J. et al. Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients. Clin. Cancer Res. 28, 2865-2877 (2022)
Weber, P. et al. Therapy-related transcriptional subtypes in matched primary and recurrent head and neck cancer. Clin. Cancer Res. 28, 1038-1052 (2022)
Anande, G.* et al. RNA splicing alterations induce a cellular stress response associated with poor prognosis inAcute Myeloid Leukemia. Clin. Cancer Res. 26, 3597-3607 (2020)
Hulstaert, E.* et al. Charting extracellular transcriptomes in The Human Biofluid RNA Atlas. Clin. Cancer Res. 26, 33-34 (2020)
Multhoff, G.* et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: A randomized phase II clinical trial. Clin. Cancer Res. 26, 5368-5379 (2020)
Hess J. et al. A five-microRNA signature predicts survival and disease control of patients with head and neck cancer negative for HPV-infection. Clin. Cancer Res. 25, 1505-1516 (2019)
Karches, C.H.* et al. Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy. Clin. Cancer Res. 25, 5890-5900 (2019)
Hensel, T.* et al. Combined targeting of the Ewing sarcoma transcriptional program by blocking epigenetic readers and transcription initiation via EWS-FLI1. Clin. Cancer Res. 24, 56-56 (2018)
Schmidt, S.* et al. Development and validation of a gene signature for patients with head and neck squamous cell carcinomas treated by postoperative radio(chemo)therapy. Clin. Cancer Res. 24, 1364-1374 (2018)
von Heyking, K.* et al. The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype promoting lung metastasis in Ewing sarcoma. Clin. Cancer Res. 24, 57-57 (2018)
Diot, G.* et al. Multi-spectral optoacoustic tomography (MSOT) of human breast cancer. Clin. Cancer Res. 23, 6912-6922 (2017)
Lamberts, L.E.* et al. Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: A phase I feasibility study. Clin. Cancer Res. 23, 2730-2741 (2016)
Friemel, J.* et al. Intratumor heterogeneity in hepatocellular carcinoma. Clin. Cancer Res. 21, 1951-1961 (2015)
Groß, C.* et al. Model matters: Differences in orthotopic rat hepatocellular carcinoma physiology determine therapy response to sorafenib. Clin. Cancer Res. 21, 4440-4450 (2015)
Lee, M.S. et al. Targeting PI3K/mTOR signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas. Clin. Cancer Res. 21, 3204-3215 (2015)
Weber, A.* ; O'Connor, T.* & Heikenwälder, M. Next generation of preclinical liver cancer models. Clin. Cancer Res. 21, 4254-4256 (2015)
Wulfkuhle, J.D.* et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin. Cancer Res. 18, 6426-6435 (2012)
Butterfield, L.H.* et al. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin. Cancer Res. 17, 3064-3076 (2011)
Ehrhardt, H. ; Wachter, F. ; Maurer, M. ; Stahnke, K.* & Jeremias, I. Important role of Caspase-8 for chemo-sensitivity of ALL cells. Clin. Cancer Res. 17, 7605-7613 (2011)
Leisegang, M.* et al. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy. Clin. Cancer Res. 16, 2333-2343 (2010)
Smida, J. et al. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin. Cancer Res. 16, 4256-4267 (2010)
Reindl, C. et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin. Cancer Res. 15, 2238-2247 (2009)
Miederer, M.* et al. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin. Cancer Res. 14, 3555-3561 (2008)
Vempati, S. et al. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. Clin. Cancer Res. 14, 4437-4445 (2008)
Lassmann, S.* et al. Predictive value of aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin. Cancer Res. 13, 4083-4091 (2007)
Napieralski, R.* et al. Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: Relation to therapy response and clinicopathologic and molecular features. Clin. Cancer Res. 13, 5095-5102 (2007)
Nößner, E. & Schleypen, J.S.* The complexity of natural killer cells. Clin. Cancer Res. 13, S. 1621 (2007)
Rauser, S. et al. Significance of HER2 low-level copy gain in Barrett's cancer: Implications for fluorescence in situ hybridization testing in tissues. Clin. Cancer Res. 13, 5115-5123 (2007)
Rokavec, M.* et al. A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk. Clin. Cancer Res. 13, 7506-7514 (2007)
Buters, J.T.M. Effective strategies for tumors affecting chemopreventive metabolism. Clin. Cancer Res. 12, 7203-7204 (2006)
Petrich, T.* et al. Effective cancer therapy with the alpha-particle ermitter [211At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors. Clin. Cancer Res. 12, 1342-1348 (2006)
Reiter, R.* et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin. Cancer Res. 12, 5136-5141 (2006)
Schleypen, J.S. et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin. Cancer Res. 12, 718-725 (2006)
von Luettichau, I.* et al. Mononuclear infiltrates in osteosarcoma and chemokine receptor expression. Clin. Cancer Res. 12, 5253-5254 (2006)
Frankenberger, B. et al. Influence of CD80 Interleukin2, and Interleukin-7 Expression in Human Renal Cell Carcinoma on the Expression, Function, and Survival of Tumor-Specific CTLs. Clin. Cancer Res. 11, 1733-1742 (2005)
Gangnus, R.* ; Langer, S. ; Breit, E.* ; Pantel, K.* & Speicher, M.R. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin. Cancer Res. 10, 3457-3464 (2004)
Gehrmann, M.* et al. Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs. Clin. Cancer Res. 10, 3354-3364 (2004)
Lindner, L.H.* et al. Novel temperature-sensitive liposomes with prolonged circulation time. Clin. Cancer Res. 10, 2168-2178 (2004)
Wahl, U. et al. Vaccination against B-cell Chronic Lymphocytic Leukemia with Trioma Cells : Preclinical Evaluation. Clin. Cancer Res. 9, 4240-4246 (2003)
Patel, V.* et al. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27KIP1. Clin. Cancer Res. 8, 3549-3560 (2002)
Specht, K. et al. Identification of Cyclin D1 mRNA Overexpression in B-Cell Neoplasias by Real-Time Reverse Transcription-PCR of Microdissected Paraffin Sections. Clin. Cancer Res. 8, 2902-2911 (2002)
Seliger, B.* et al. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin. Cancer Res. 3, 573-578 (1997)